<DOC>
	<DOCNO>NCT00301899</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab pertuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving trastuzumab together pertuzumab may kill tumor cell . PURPOSE : This phase II trial study well give trastuzumab together pertuzumab work treat patient unresectable locally advanced metastatic breast cancer respond previous trastuzumab .</brief_summary>
	<brief_title>Trastuzumab Pertuzumab Treating Patients With Unresectable Locally Advanced Metastatic Breast Cancer That Did Not Respond Previous Trastuzumab</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient HER2/neu-overexpressing , inoperable locally advanced metastatic breast cancer refractory trastuzumab ( Herceptin® ) -based therapy treat trastuzumab pertuzumab . - Determine safety tolerability regimen patient . Secondary - Determine time progression , progression-free survival , duration response , percentage patient free disease progression 3 , 6 , 12 month . - Correlate pre-treatment HER-2/neu phosphorylation phosphorylation downstream marker signal pathway use tumor tissue blood pertuzumab sensitivity and/or trastuzumab resistance patient . OUTLINE : This open-label study . Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 pertuzumab IV 30-60 minute day 2 course 1 . Beginning course 2 subsequent course , patient receive trastuzumab pertuzumab day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer 1 follow stage : Metastatic disease ( stage IV ) Inoperable locally advance disease Disease progression prior neoadjuvant chemotherapy require Disease progression trastuzumab ( Herceptin® ) basedtherapy Received 13 prior trastuzumabbased regimen HER2/neupositive tumor , define 3+ fluorescent situ hybridization Measurable disease , define least 1 lesion measure least one dimension No clinical sign symptom brain and/or leptomeningeal metastasis confirm CT scan MRI Brain and/or leptomeningeal metastasis allow patient stable lesion standard treatment ( surgery radiotherapy ) , asymptomatic neurological exam , receive corticosteroid therapy control symptoms Hormone receptor status : Not specify PATIENT CHARACTERISTICS : ECOG performance status 01 Male female Menopausal status specify Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Alkaline phosphatase &lt; 5 time ULN AST ALT ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) LVEF low limit normal echocardiogram MRI No clinical sign symptom heart failure No uncontrolled hypertension ( i.e. , blood pressure ≥ 180/100 mm Hg ) No significant valvular disease ( i.e. , aortic mitral regurgitation 3 4+/4+ severity stenosis either valve ) No history uncontrolled cardiac arrhythmia No symptomatic asymptomatic myocardial infarction No angina pectoris require medication No document significant cardiac event No poorly control diabetes mellitus ( i.e. , fast blood sugar ≥ 200 mg/dL ) No history hypersensitivity reaction trastuzumab No AIDS No nonmalignant condition require ≥ 20 mg prednisone ( equivalent ) No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No ongoing liver disease , include viral hepatitis , alcohol abuse , cirrhosis No serious medical illness No medical psychiatric condition would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 3 week since prior investigational anticancer agent More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) , major surgery , immunotherapy More 4 week since prior radiotherapy except shortcourse palliative radiotherapy bone pain More 2 week since prior concurrent oral hormonal therapy More 4 week since prior fulvestrant No prior doxorubicin hydrochloride doxorubicin HCl liposome cumulative dose &gt; 360 mg/m^2 No prior mitoxantrone hydrochloride cumulative dose &gt; 120 mg/m^2 No prior epirubicin hydrochloride cumulative dose &gt; 600 mg/m^2 No prior idarubicin cumulative dose &gt; 90 mg/m^2 No concurrent radiation therapy , include symptomatic bone metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>